Unmet needs in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 7, Issue SUPPL. 3, 2005, Pages

  Moreland, Larry ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; B7 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 IMMUNOGLOBULIN FUSION PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTHROPATHY; BACTERIAL INFECTION; BONE EROSION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST OF ILLNESS; CYTOKINE RELEASE; DEMYELINATION; DOSE CALCULATION; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; ENZYME INHIBITION; FINANCIAL MANAGEMENT; HEMATOLOGIC DISEASE; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; LIVER TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; MYCOSIS; PATIENT SELECTION; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SHORT FORM 36; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VASCULITIS; WORKING TIME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 21644446058     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1736     Document Type: Review

References (25)

1. American College of Rheumatology Subcommittee on Rheumatology Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 2002, 46:328-346.
2. Goekoop-Ruiterman YPM, Vries-Bouwstra K, Van Zeben D, Kerstens PJS, Hazes JMW, Zwinderman AH, Breedveld FC, Allaart CF, Dijkmans BAC: Treatment strategies in early rheumatoid arthritis: clinical and radiological outcomes after 2 year follow-up of the BsSt study (abstract]. In Program Book Supplement to the 2004 ACR/ARHP Annual Scientific Meeting; 16-21 October 2004; San Antonio, TX. Abstract L4. Hoboken NJ: John Wiley & Sons; 2004.
3. Breedveld FC, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhaven R, Perez JL, Spencer-Green GT, Weisman MH: Early treatment of rheumatoid arthritis with adalimumab plus methotraxate vs. adalimumab alone or methotrexate alone: the PREMIER study [abstract]. In Program Book Supplement to the 2004 ACR/ARHP Annual Scientific Meeting; 16-21 October 2004; San Antonio, TX. Abstract L5. Hoboken NJ: John Wiley & Sons; 2004.
4. van der Heijde D, Klareskog L, Wajdula J, Pedersen R, Fatenejad S, for the TEMPO Study Investigators: Halting of radiographic progression in RA patients treated with etanercept and methotrexate: year 2 results from the TEMPO trial [abstract]. In Program Book Supplement to the 2004 ACR/ARHP Annual Scientific Meeting; 16-21 October 2004; San Antonio, TX. Abstract L11. Hoboken NJ: John Wiley & Sons; 2004.
5. St Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, et al., Active Controlled Study of Patient Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004, 50:3432-3443.
6. Silverman GJ, Carson DA: Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003, Suppl 4:S1-S6.
7. Edwards JC, Szczepański L, Szechiński J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
8. Scott DL, Symmons DP, Coulton BL, Popert AJ: Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987, 1:1108-1111.
9. Pinkus T, Callahan LF: Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986, 13:841-845.
10. Yelin E, Wanke LA: An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999, 42: 1209-1218.
11. Cooper NJ: Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000, 39:28-33.
12. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, et al.: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann Intern Med 2002, 137:726-733.
13. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996, 334:1287-1291.
14. Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344:907-916.
15. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915.
16. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, et al.; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004, 363:675-681.
17. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
18. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
19. Breedveld FC, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Perez JL, Spencer-Green GT, Weisman MH: Early treatment of rheumatoid arthritis (RA) with adalimumab (humira®) plus methotrexate vs. adalimumab alone or methotrexate alone: the PREMIER study. In Program Book Supplement to the 2004 ACR/ARHP Annual Scientific Meeting; 16-21 October 2004; San Antonio, TX. Presentation L5. Hoboken NJ: John Wiley & Sons; 2004.
20. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA, et al.; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051-1065.
21. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al.; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602.
22. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:614-624.
23. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, et al.; 990145 Study Group: A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004, 63:1062-1068.
24. Kremer J, Westhovens R, Moreland L, Emery P, Russell A, Ge Z, Aranda R, Becker JC: Efficacy and safety of the selective co-stimulation modulator abatacept with methotrexate for treating rheumatoid arthritis: 1-year clinical and radiographic results from the phase III AIM (Abatacept in Inadequate responders to Methotrexate) trial [abstract]. In Program Book Supplement to the 2004 ACR/ARHP Annual Scientific Meeting; 16-21 October 2004; San Antonio, TX. Abstract L2. Hoboken NJ: John Wiley & Sons; 2004.
25. Patlak M: Options, challenges in treating RA. In ACP Observer 2004. [http://www.acponline.org/journals/news/oct04/ra.htm] (last accessed 24 March 2005). 2004.